Teva Pharmaceutical Launches Generic Pataday in the U.S.

Teva Pharmaceutical Industries has launched generic Pataday (olopatadine hydrochloride ophthalmic solution) 0.2% in the U.S. to treat ocular itching associated with allergic conjunctivitis.

Shares of Teva are up 1.8% in pre-market trading. “Olopatadine hydrochloride ophthalmic solution 0.2% is an important treatment for our patients, and a key addition to our generics product portfolio,” said Dipankar Bhattacharjee, CEO of Teva’s global generic medicines group. Pataday had annual sales of approximately $303 million in the U.S., according to IMS data as of March 2017.

Add Comment